



Final programme

Moderators:

Morgan Roupret, Paris (FR)
Arnulf Stenzl, Tübingen (DE)

13.00 – 14.00 Update on staging of PCa

13.00 – 13.10 Magnetic Resonance Imaging (bp or mpMRI) for diagnosis and staging

Jochen Walz, Marseille (FR)

13.10 - 13.15 *Discussant*

Jan-Philipp Radtke, Essen (DE)

13.15 – 13.25 PSMA based imaging in primary and recurrent disease

Jan-Philipp Radtke, Essen (DE)

13.25 – 13.30 *Discussant*

Jochen Walz, Marseille (FR)

13.30 – 13.35 Breaking news from the Guidelines 2020 on staging

Nicolas Mottet, Saint-Étienne (FR)

13.35 – 14.00 What is the best and most effective staging in 2020? (interactive case discussions)

P. Cornford, Liverpool (GB)

Jan-Philipp Radtke, Essen (DE)

Jochen Walz, Marseille (FR)

14.10 – 15.10 Update on the treatment of recurrent disease

14.10 – 14.20 BCR after surgery: early or late salvage RT

Gert De Meerleer, Leuven (BE)

14.20 – 14.25 *Discussant*

Alberto Briganti, Milan (IT)

14.25 – 14.35 Management of oligometastatic recurrence

Alberto Briganti, Milan (IT)

14.35 – 14.40 *Discussant*

Gert de Meerleer, Leuven (BE)

14.40 – 14.45 Breaking news from the Guidelines 2020 on recurrent disease

Nicolas Mottet, Saint-Étienne (FR)

14.45 – 15.10 The best timing of different forms of treatment in recurrent disease (Interactive Case Discussion)

Alberto Briganti, Milan (IT)

Gert De Meerleer, Leuven (BE)

Jeroen Van Moorselaar, Amsterdam (NL)

15.10 – 15.20 Timing of radiotherapy after radical prostatectomy

Derya Tilki, Hamburg (DE)

15.20 – 16.20 Update on the treatment of de novo low-volume mHSPC

15.20 – 15.30 How to manage node positive (cN1/cM1a) PCa

Steven Joniau, Leuven (BE)

15.30 – 15.35 *Discussant*

Jeroen Van Moorselaar, Amsterdam (NL)

15.35 – 15.45 Management options of low-volume mHSPC

Jeroen Van Moorselaar, Amsterdam (NL)

15.45 – 15.50 *Discussant*

Steven Joniau, Leuven (BE)

15.50 – 15.55 Breaking news from the Guidelines 2020 on staging and treatment of HSPC

Nicolas Mottet, Saint-Étienne (FR)

15.55 – 16.20 How much local treatment for low volume mHSPC? (Interactive Case Discussion)

Jeroen Van Moorselaar, Amsterdam (NL)

Nicola Fossati, Milan (IT)

Steven Joniau, Leuven (BE)

16.30 – 17.30 Update on the treatment of CRPC

16.30 – 16.40 Update on the management of non-metastatic CRPC

Axel Merseburger, Lübeck (DE)

16.40 – 16.45 *Discussant*

Joaquim Bellmunt, Barcelona (ES)

16.45 – 16.55 New developments in the management of mCRPC

Joaquim Bellmunt, Barcelona (ES)

16.55 – 17.00 *Discussant*

Marc-Oliver Grimm, Jena (DE)

17.00 – 17.05 Breaking news from the Guidelines 2020 on CRPC

Nicolas Mottet, Saint-Étienne (FR)

17.05 – 17.30 Best sequence of CRPC (Interactive Case Discussion)

Joaquim Bellmunt, Barcelona (ES)

Marc-Oliver Grimm, Jena (DE)

Axel Merseburger, Lübeck (DE)